Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
Pyxis Oncology, Inc. (NASDAQ:PYXS) announced on Thursday, a portfolio prioritization, focusing resources on advancing its lead clinical program, PYX-201.
Pyxis Oncology, Inc.（納斯達克：PYXS）在週四宣佈了一項投資組合優先級，專注於將資源用於推進其主要臨牀項目PYX-201。
Pyxis Oncology's second clinical program, PYX-106, is being deprioritized to allocate resources toward advancing the lead asset, PYX-201.
Pyxis Oncology的第二個臨牀項目PYX-106被降級優先級，以便將資源分配給推進主要資產PYX-201。
As a result, Pyxis Oncology has decided to suspend further clinical investment in PYX-106, which was in-licensed from Biosion Inc., with Biosion retaining rights for Greater China.
因此，Pyxis Oncology決定暫停對PYX-106的進一步臨牀投資，該項目是從Biosion Inc.引進的，Biosion保留大中華地區的權利。
Also Read: Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
另請閱讀：Pyxis Oncology的癌症藥物進展引發分析師關注
In November, Pyxis Oncology reported preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating its safety and efficacy in multiple solid tumor types.
在11月，Pyxis Oncology報告了PYX-201正在進行的I期劑量遞增研究的初步數據，評估其在多種實體瘤類型中的安全性和有效性。
Among patients with HNSCC, PYX-201 achieved a confirmed 50% objective response rate (ORR), including one complete response and a disease control rate (DCR) of 100% in six heavily pretreated HPV-positive and HPV-negative evaluable patients with a median of four prior lines of therapy.
在HNSCC患者中，PYX-201的確認客觀反應率（ORR）達到了50%，包括1例完全反應和6名經過重度治療的HPV陽性和HPV陰性可評估患者的疾病控制率（DCR）爲100%，中位數接受了四個前線治療。
Across six solid tumor types of interest at therapeutically active dose levels, including HNSCC, ovarian, non-small cell lung cancer (NSCLC), HR+/HER2- breast cancer, triple-negative breast cancer (TNBC) and sarcoma, PYX-201 (n=31) achieved a 26% ORR in the Phase 1 trial, with dose-dependent responses observed.
在包括HNSCC、卵巢癌、非小細胞肺癌（NSCLC）、HR+/HER2-乳腺癌、三陰性乳腺癌（TNBC）和肉瘤在內的六種實體瘤類型的治療有效劑量水平中，PYX-201（n=31）在I期試驗中達到了26%的ORR，觀察到劑量依賴性的反應。
The portfolio prioritization further supports a development plan for PYX-201 in several dose expansion studies, including monotherapy in 2/3L HNSCC, in combination with pembrolizumab in 1/2L+ HNSCC, and pembrolizumab combination studies in other solid tumors including HR+/HER2- and triple-negative breast cancer.
該投資組合優先級進一步支持PYX-201在多個劑量擴展研究中的開發計劃，包括在2/3L HNSCC中的單藥治療、在1/2L+ HNSCC中與pembrolizumab的聯合治療，以及在其他實體瘤（包括HR+/HER2-和三陰性乳腺癌）中的pembrolizumab聯合研究。
Preliminary data from these cohorts are expected in the second half of 2025 and the first half of 2026.
這些隊列的初步數據預計將在2025年下半年和2026年上半年公佈。
"Given the historical development challenges associated with anti-siglec-15 antibodies, we believe that the Street expectations were low heading into the initial data readout for PYX-106," said the William Blair analyst.
「鑑於與抗siglec-15抗體相關的歷史開發挑戰，我們相信在PYX-106的初步數據公佈前，市場的預期較低，」威廉·布萊爾分析師說。
The company's current cash position is expected to fund its planned monotherapy and combination therapy trials of PYX-201 into the second half of 2026.
公司目前的現金狀況預計將支持其計劃中的PYX-201單藥治療和聯合療法試驗，直到2026年下半年。
The analyst says it supports management's decision to stop investing in the program. While PYX-201 showed some activity, it likely won't significantly change head and neck cancer treatment.
分析師表示，這支持管理層停止對該項目進行投資的決定。雖然PYX-201顯示出一些活性，但它可能不會顯著改變頭頸癌的治療。
PYXS Price Action: PYXS Oncology stock is up 1.30% at $1.56 at publication Friday.
PYXS股價動態：公開時PYXS癌症股票上漲1.30%，報$1.56。
- Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?
- 爲什麼癌症專注的Aadi生物科技股票在星期五交易更高？
This image was created using artificial intelligence MidJourney.
此圖像是使用人工智能MidJourney創建的。
譯文內容由第三人軟體翻譯。
